Avidity Biosciences, Inc. (RNA)
NASDAQ: RNA · Real-Time Price · USD
33.92
+0.39 (1.16%)
At close: Jul 23, 2025, 4:00 PM
33.32
-0.60 (-1.77%)
After-hours: Jul 23, 2025, 7:52 PM EDT
Avidity Biosciences Revenue
Avidity Biosciences had revenue of $1.57M in the quarter ending March 31, 2025, a decrease of -55.60%. This brings the company's revenue in the last twelve months to $8.93M, down -17.87% year-over-year. In the year 2024, Avidity Biosciences had annual revenue of $10.90M with 13.99% growth.
Revenue (ttm)
$8.93M
Revenue Growth
-17.87%
P/S Ratio
458.01
Revenue / Employee
$22,831
Employees
391
Market Cap
4.09B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
Novartis AG | 55.19B |
AstraZeneca | 54.98B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
RNA News
- 17 hours ago - Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping - PRNewsWire
- 6 weeks ago - Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research Congress - PRNewsWire
- 6 weeks ago - Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE™ Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants - PRNewsWire
- 6 weeks ago - Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD™ Study in FSHD - PRNewsWire
- 2 months ago - Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 2 months ago - Avidity Biosciences Reports First Quarter 2025 Financial Results and Recent Highlights - PRNewsWire
- 2 months ago - Avidity Biosciences to Participate in Upcoming Investor Conference - PRNewsWire
- 3 months ago - Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1 - PRNewsWire